Table 3.

Clinical effectiveness in EVOLVE.

	UC			CD
First-line vedolizumab or first-line anti-TNF over 24 months
	First-line vedolizumab	First-line anti-TNF	p Value	First-line vedolizumab	First-line anti-TNF	p Value
Clinical remission	65.9%	48.6%	0.09	76.6%	68.5%	0.10
Clinical response	88.3%	86.2%	0.64	84.0%	72.1%	0.27
Mucosal healing	86.6%	80.6%	0.66	100%	90.4%	0.12
First-line anti-TNF or second-line anti-TNF at 3 or 6 months
	First-line anti-TNF	Second-line anti-TNF	p Value	First-line anti-TNF	Second-line anti-TNF	p Value
Clinical remission at 3 months	9.7%	11.0%	0.92	22.9%	49.2%	0.02
Clinical response at 3 months	38.4%	44.8%	0.54	30.1%	41.3%	0.52
Clinical remission at 6 months	19.6%	14.7%	0.69	36.2%	74.6%	<0.01
Clinical response at 6 months	57.1%	61.1%	0.58	43.5%	74.8%	0.13

p Values in bold italics are statistically significant.

CD, Crohn’s disease; TNF, tumor necrosis factor; UC, ulcerative colitis.